Trial Profile
Treatment of advanced renal cell carcinoma with axitinib: association of pharmacokinetics with treatment outcome and adverse events
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2019
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 21 May 2018 Results (n=44) assessing Serum Biomarkers to Predict Axitinib Efficacy, presented at the 113th Annual Meeting of the American Urological Association
- 21 May 2018 Results (n=80) the impact of Polymorphism in Vascular Endothelial-Related Genes on Clinical Response to Axitinib, presented at the 113th Annual Meeting of the American Urological Association
- 16 May 2017 Results (n=53) assessing relationships between genetic polymorphisms, the frequency of adverse events, objective responses, and survival, presented at the 112th Annual Meeting of the American Urological Association